Semaglutide CoA: What to Check in HPLC Purity Data

When procurement teams ask semaglutide CoA what to check, the honest answer is that most CoAs are read too shallowly. A purity figure of 98.5% tells you almost nothing unless you know which method produced it, how that method was validated, and whether the chromatogram in front of you belongs to the lot you are buying. This guide walks through the HPLC purity testing workflow for GLP-1 peptides from method development through validation, and it includes the failure cases that generic supplier pages tend to omit.

Why Semaglutide CoA Review Starts With the Method, Not the Number

Semaglutide is a 31-amino-acid GLP-1 analog with a fatty-acid side chain and a non-natural amino acid at position 8. That structure creates analytical challenges that a generic reverse-phase gradient will not resolve. Related impurities — desamido forms, acyl migration products, diastereomers, and chain-shortened fragments — often elute close to the main peak. If the method does not separate them, the reported purity is inflated.

Before you accept any purity value, confirm the CoA states the column chemistry, dimensions, particle size, mobile phase composition, gradient program, detection wavelength, flow rate, and injection volume. A CoA that lists only "HPLC: 98.7%" is not a CoA; it is a marketing line.

Method Development Specifics for GLP-1 Peptides

In our laboratory experience, semaglutide methods typically require a C18 column with sub-3 µm particles and a shallow gradient (often 0.3–0.5% B per minute) over 30–45 minutes to resolve the desamido and acyl-migration species. Trifluoroacetic acid at 0.1% in both aqueous and organic phases is standard, but TFA concentration drift is a common source of retention-time shifting between labs. Detection at 214 nm is typical for the peptide backbone, though 280 nm can be added for aromatic residues.

For tirzepatide, the 39-residue sequence and C20 diacid side chain demand even shallower gradients and longer run times. If a supplier reports the same method for semaglutide and tirzepatide without modification, that is a red flag worth documenting.

Validation Parameters That Belong on a Semaglutide CoA

A validated HPLC method is not the same as a method that has been run once. The CoA should reference validation data for at least the following parameters:

• Specificity: resolution between the main peak and the nearest impurity, typically ≥1.5.
• Linearity: R² ≥0.999 across the working concentration range.
• Accuracy: spike yield within 98–102% at three levels.
• Precision: repeatability RSD ≤1.0% and intermediate precision RSD ≤2.0%.
• Limit of detection and quantitation: LOD and LOQ stated for the main impurity classes.
• Robustness: documented tolerance to ±2% organic phase, ±0.5 °C column temperature, and ±0.1 pH unit.

If the CoA does not state these, ask for the validation summary. A supplier who cannot produce it is asking you to trust an unvalidated number.

Mass Balance and Assay vs Purity

HPLC purity is a relative area percentage. It does not tell you the mass of peptide in the vial. Assay by elemental analysis, nitrogen determination, or quantitative amino acid analysis gives the absolute content. A CoA that reports 99% HPLC purity but 78% assay is describing a sample that is mostly water and counterion. For research applications where molar accuracy matters, both values belong on the CoA.

Our CoA review guide covers the full document structure, including how to cross-check assay against Karl Fischer water content and residual TFA.

Real Failure Cases From the Bench

Three failure modes come up repeatedly in incoming CoA audits.

Case 1: The Overloaded Injection

A lot reported 99.2% purity by HPLC. On re-analysis at a lower injection load, the main peak split into two partially resolved peaks, and the true purity was 96.8%. The original method had injected 50 µL of a 2 mg/mL solution onto a 4.6 mm column, overloading the stationary phase and masking the impurity. The address is to specify injection volume and column load on the CoA, not just the percentage.

Case 2: The Wrong Wavelength

A supplier reported purity at 280 nm. Semaglutide has weak aromatic absorbance, so the signal-to-noise at 280 nm was poor, and small impurities were below the detection threshold. Re-running at 214 nm revealed a desamido impurity at 1.4%. The CoA should state the detection wavelength and, ideally, include a second wavelength for confirmation.

Case 3: The Missing Chromatogram

A CoA listed 98.9% purity with no chromatogram attached. When we requested the raw data file, the retention time did not match the method described in the CoA header. The batch had been run on a different column. Without the chromatogram, there is no way to verify that the method and the result belong together. Always request the chromatogram and the method file.

For a step-by-step walkthrough of how these checks map onto a tirzepatide CoA, see our tirzepatide CoA guide.

Batch Traceability and the Semaglutide CoA

The CoA must be traceable to a specific lot. Check that the lot number on the CoA matches the lot number on the vial label, the packing slip, and the certificate of origin. If the CoA references a batch number that does not appear on any shipping document, the document chain is broken.

Retatrutide certificate of analysis review follows the same logic, though the triple-agonist structure introduces additional impurity classes that require a wider gradient. The principle is identical: the document must tie a method, a result, and a physical lot together.

Checklist for Institutional Buyers

• Method details: column, mobile phase, gradient, wavelength, flow rate, injection volume.
• Validation summary: specificity, linearity, accuracy, precision, LOD/LOQ, robustness.
• Chromatogram attached and consistent with the stated method.
• Assay value alongside HPLC purity.
• Water content and residual counterion data.
• Lot number match across CoA, label, and shipping documents.
• Independent third-party verification available on request.

What to Ask Before You Release a Batch

For research procurement, the semaglutide CoA what to check question reduces to three verifications: the method is fit for GLP-1 peptides, the validation data supports the reported purity, and the document chain ties the result to the lot you received. If any of those is missing, request the underlying data before releasing the batch to laboratory use.

Helix Peptide supplies GMP-grade GLP-1 peptides with full method documentation and lot-level traceability. To discuss a specific CoA or request a quote, talk to our QA team.